News

CNC, ADM, AVT, ARW and AMN emerge from a broker-focused screen as Iran-U.S. tensions, rising oil prices and rate uncertainty cloud markets.

CNC, ENS and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 25th, 2026.

UnitedHealth, The Cigna, Humana, Centene and Molina have been highlighted in this Industry Outlook article.

Medicare's improvement is real but not a turn in cost trend, while commercial costs keep running higher and the margin fix there has slipped again.

An aging U.S. population, digital transformation, a diversified membership mix and strategic M&A are likely to drive the performance of the Zacks Medical-HMO industry players. UNH, CI, HUM, CNC and MOH are poised to benefit from favorable industry prospects.

The healthcare giant is wrestling with costs in one part of its business, and the stock's recent dip has investors wondering if this is the moment to step in.

EHC's rising demand, higher patient acuity and hospital expansion support growth, while rising expenses and debt remain key risks.

Centene Corporation recently announced that long-serving CFO Drew Asher will step down from his role at the end of 2026, with former Lincoln Financial executive Chris Neczypor set to join in September and assume the Executive Vice President and Chief Financial Officer position on January 1, 2027. The planned overlap between Asher and Neczypor, following a period in which Centene’s revenue grew from about US$126.00 billion in 2021 to about US$195.00 billion in 2025, highlights an emphasis on...

Aon expects U.S. employer health-care costs to rise 9.5% in 2027, intensifying pressure on benefits budgets and demand for cost-management services.

CNC, ENS and VLO made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 21st, 2026.

A rate hike could keep markets volatile, making BVS, CNC, AMRX and CRON healthcare stocks to consider as inflation stays elevated.

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 27.5% gain over the past six months, beating the S&P 500 by 16.2 percentage points.

CI's growth and shareholder returns are weighed against rising costs, medical expenses and debt, keeping investors neutral for now.

CNC, ATI and MNDY made it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 18, 2026

Five top-ranked stocks, including Centene and Fortinet, stand out for strong earnings-surprise histories that could support future beats.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Top-ranked stocks CNC, THC, FTNT, U and GS are likely to beat on the bottom line in their upcoming releases.

Chris Neczypor, the finance chief at Lincoln Financial, will succeed Drew Asher on Jan. 1. Asher plans to retire at the end of 2027.

Each stock in this article is trading near its 52-week high. These elevated prices usually indicate some degree of investor confidence, business improvements, or favorable market conditions.

Recent commentary on Centene (CNC) has focused on a fresh debt redemption plan and higher expectations for revenue and earnings, which together are shaping how investors view the stock’s profitability potential. See our latest analysis for Centene. Centene’s share price has climbed strongly over 2026, with a year to date share price return of 58.07% and a 90 day move of 13.33%, while the 1 year total shareholder return of 145.23% suggests momentum has been building as investors respond to...

Five stocks stand out as potentially undervalued by price-to-book measures, including BioMarin Pharmaceutical, Invesco and Centene.

Centene stock has surged over the past year, yet the current checks still suggest it leans on the cheap side, so investors are weighing how much of the recent optimism is already reflected in the price. Centene has returned 145.2% over the past year, which puts a spotlight on whether the recent share price strength is outpacing the underlying fundamentals. Raised expectations for future revenue and earnings, together with a plan to redeem part of its debt, can support the case for improved...

Management had named the plan exits, the Medicare margin target and the repricing date before the run began.

MD's stronger cash collections, favorable payer mix, acquisitions and telehybrid care support its growth prospects.

BioMarin, Invesco, Centene, HPE and Gibraltar Industries stand out as undervalued stocks with low price-to-book ratios.

SNDR, CNC, and TAL it to the Zacks Rank #1 (Strong Buy) growth stocks list on August 13, 2026.

Boeing upgraded, Under Armour downgraded: Wall Street's top analyst calls

CNC and BEN have surged 61.7% and 40.3%, respectively, year to date, while disciplined execution and attractive valuations support their outlook.

While the S&P 500 (^GSPC) includes industry leaders, not every stock in the index is a winner. Some companies are past their prime, weighed down by poor execution, weak financials, or structural headwinds.

In the health insurance arena, one company is both the undisputed leader and the most expensive ticket, forcing investors to decide if paying up for quality is a winning strategy.